1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH and CDC Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Required) is sponsored by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). This program supports U.S. small businesses in developing innovative health-related technologies through phased research and development, including clinical trials.
It aims to advance projects aligned with NIH and CDC missions, encouraging collaborative, high-impact solutions with commercialization potential.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible U.S. small business concerns. Clinical trials are required. Confirm the full requirements in the official notice before applying.
The current listing shows phase I up to $323,090, Phase II up to $2,153,927 (SBA guideline; some ICs higher). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NIH and CDC Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Required) are due January 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NIH and CDC Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Required) is funded by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PHS 2023 Omnibus Solicitation of the NIH and CDC for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). This omnibus solicitation encourages small businesses to collaborate with non-profit research institutions on research and development projects related to the mission of NIH and CDC.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs (Omnibus/Parent Funding Opportunity Announcements) is sponsored by National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC). The NIH and CDC SBIR/STTR programs are one of the largest sources of early-stage capital for technology commercialization in the United States, enabling US-owned and operated small businesses to conduct research and development that has a strong potential for commercialization i…
PA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read articleNOT-OD-26-098 consolidates NIH career development awards into four parent NOFOs (KR1, KC1, KS1, KT1), eliminates the Data Management and Sharing Plan for K applications, and stops supporting K awards that let the awardee lead their own clinical trial. The RFI closes September 30, 2026; the new structure hits due dates on or after October 12, 2027.
Read articleThe Health and Extreme Weather highlighted topic went live September 1, 2026 with eleven awarding institutes and expires May 1, 2028. There is no set-aside, no separate deadline, and no review criteria — which makes the institute-by-institute language the only real signal, and it is not uniform.
Read article